S&P: Merck on Watch for Debt Downgrade

The rating agency's big concern: the magnitude of possible litigation against the AAA-rated drugmaker after its Vioxx withdrawal

By Arthur Wong

To continue reading this article you must be a Bloomberg Professional Service Subscriber.